

Press release

Lund 25 October 2021

## Scandinavian ChemoTech's subsidiary Vetiqure has received a preliminary positive treatment result

***Preliminary results of the first TSE treatment at Evidensia Specialistdjursjukhuset Helsingborg point to a result that is better than expected.***

The patient is a dog with a tumour in the palate roof where previous radiotherapy and local chemotherapy have been shown to have insufficient effect.

*"We are awaiting more information but continue to view the development very positively."* - says veterinarian Majbritt Larsen, who is responsible for the Oncology team in Helsingborg.

*For more information, please contact:*

Mohan Frick, CEO

+46 (0)10-218 93 00

[info@chemotech.se](mailto:info@chemotech.se)

***Certified Adviser:*** Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

*This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-10-2021 16:30 CET.*

### **Scandinavian ChemoTech AB (publ)**

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: [www.chemotech.se](http://www.chemotech.se)